Lisata Therapeutics, based in Basking Ridge, New Jersey, focuses on developing therapies for advanced solid tumors, with its lead candidate LSTA1 enhancing anti-cancer drug penetration in tumors. The company also explores CD34+ cell therapy for various diseases, including critical limb ischemia and diabetic kidney disease.
LSTA has been in the news recently: Waters Corporation is merging with Becton, Dickinson and Company (BD) to form a $17.5 billion company, significantly expanding its market potential to $40 billion and projecting $6.5 billion in sales by 2025. Meanwhile, Neurocrine Biosciences, Inc. reported positive treatment outcomes for adults with classic congenital adrenal hyperplasia using their product CRENESSITY.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
